Clinical Trials Browser

INDUSTRY × Recurrence × pomalidomide × Clear all

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence

Multiple Myeloma, Neoplasms, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Multiple Myeloma, Recurrence

Clinical Trials

SUCCESSOR-1

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

STOMP

MonumenTAL-3

MajesTEC-9

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

SELECT

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Pomalyst PMS

INTREPID-1

A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

ALUMMINATE

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

FUSIONMM-003

KarMMa-3

A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

STRATUS

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

PEXIUS

NIMBUS

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma